In the age of big data, genomics and clinical research have reached a crossroads. A wealth of data is being generated, but it is becoming increasingly complicated to analyze these data to extract meaningful results. The ability to understand biological systems holistically has unprecedented potential to transform how cancers are treated. Recent major advances leading biomedical research towards "systems medicine" have been fueled by high-throughput platforms, such as microarrays and next-generation sequencing, which can capture vast amounts of data in different genomic spaces. Unfortunately, because of high dimensionality and complex relationships among these data, inferring comprehensive and useful biological models has proven computationally and statistically challenging. However, novel bioinformatic methods for data integration of cancer genomic datasets have been developed. In this review, we will describe the applications of various genomic approaches in sarcoma research and introduce bioinformatic methods for data integration. With the continuing evolution of technological and bioinformatic methodologies, the application of big data within clinics and hospitals will ultimately result in significant improvements on how cancers are detected and treated.
Introduction
Since German biologist Theodor Boveri in his seminal paper "Concerning the Origin of Malignant Tumor" [1] first proposed in 1914 that cancers are the result of chromosomal abnormalities, cancer has been considered a genetic disease. Genomic aberrations crucial for tumor initiation, development, and progression have been elucidated in cancers [2] [3] [4] [5] . However, it was difficult to simultaneously characterize all the genomic changes in a tumor in the past. With the advent of the genomic technologies, we are witnessing an explosion of genomic data. Hence, genomics and clinical research are at a crossroads as it becomes increasingly more complicated to extract meaningful results from complex and multi-layered genomic information. Recent advances in high-throughput platforms have dramatically improved the discovery of genomic aberrations in various cancers and their subtypes.
As the costs of these genomic assays are rapidly declining, analyzing the entire genomic landscape of different cancers to determine common dysregulations is becoming a reality.
Some of the well-known cancer genomics efforts include
The Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) projects by the National Cancer Institute, as well as the Cancer Genome Project by the International
Cancer Genome Consortium [6] [7] [8] . The common theme 178 doi:10.18282/amor.v3.i4.236 among these initiatives is that hundreds of specimens from each tumor type are characterized by multiple genomic and proteomic platforms to elucidate the genomic landscapes of the tumor. These platforms include DNA sequencing, DNA copy number analysis, methylation analysis, RNA sequencing (RNA-seq) or expression profiling, microRNA (miRNA) profiling, and other genomic/proteomicbased methods. The current challenge of the field is to comprehensively and effectively analyze different sources of genomic data and transform them into knowledge that can improve cancer diagnosis and treatment. To achieve this goal, data integration approaches that can lead to biological or clinical discoveries are critically needed. In this review, we provide an overview of genomic analyses and applications in sarcoma research (Figure 1) . We also introduce data integration approaches that have been successfully applied in genomic research.
DNA mutation and copy number analysis
Genetic aberrations are considered to be the major pathogenic mechanisms underlying cancer. Nonetheless, many studies have shown that mutations in a single gene are not sufficient to develop full malignancy for most tumor types [9] . Instead, tumorigenesis represents a "multiple-hit" process consisting of amplifications or activating mutations of oncogenes, and deletions or loss of heterozygosity of tumor suppressor genes [10] . As described by Vogelstein et al., the genomic landscape of human cancer reveals that a typical tumor is caused by mutations in two to eight "driver genes" [11] . Therefore, systematic and comprehensive identification of these genomic aberrations can provide important information for diagnosis, prognostication, and therapy for cancer. For instance, deficient DNA mismatch repair has been identified in colorectal cancer, which is characterized by high microsatellite instability (MSI-H) [12] . The MSI-H tumors have distinct biological properties, including an increased level of antigenicity due to accumulation of multiple mutations [13] . Recently, the Food and Drug Administration (FDA) approved pembrolizumab, an immune checkpoint inhibitor, for the treatment of MSI-H or mismatch-repair deficient solid tumors. Pembrolizumab is emerging as a first-line therapy for certain cancers, such as lung cancer, that express programmed death-ligand 1 (PDL1) [14] . This represents a paradigm shift in drug development as this drug was approved based on a tumor biomarker rather than the tumor type or organ of origin. In sarcoma research, Man et al. have reported the first application of array-based comparative genomic hybrid ization (aCGH) in osteosarcoma, which identified distinct amplifications and deletions that represent potential therapeutic targets [15] . Similarly, using aCGH and expression arrays, Savola et al. have identified important copy number aberrations (CNAs) in Ewing sarcoma and correlated the number of CNAs in the tumor to patient's survival [16] . The study has detected copy number changes in 87% of the cases, and the most recurrent CNAs are gains at chromosome 1q 2, 8, and 12, and losses at 9p and 16q. The cumulative event-free and overall survival rates were significantly better for primary tumors with three or less copy number changes than for tumors with higher numbers of CNAs. Single nucleotide polymorphism (SNP) arrays have also been widely used in copy number variations (CNVs) analysis in normal tissues and CNAs analysis of tumors, which could improve the yield in both constitutional and cancer genome diagnostics [17] . Using an SNP microarray approach, Lynn et al. have identified tumor-specific CNAs in Ewing sarcoma, which include genes known to be involved in Ewing sarcoma (e.g., CDKN2A), but also novel genes not previously associated with the sarcoma (e.g., SOX6 and PTEN) [18] . Recurrent amplification and overexpression of the FGFR1 gene have been reported in multiple soft-tissue sarcoma subtypes using aCGH, RNA-seq, and SNP arrays. The genomic alterations affect the sensitivity of soft-tissue sarcoma cells towards FGFR inhibitors [19] . These studies exemplify that aCGH and SNP arrays are effective methods for identifying genomic regions and their associated genes involved in tumorigenesis, and for identifying novel therapeutic targets for the development of treatment strategies in aggressive sarcomas [18] .
In addition to CNA analysis, researchers have been increasingly using next-generation sequencing (NGS) technologies to analyze the entire genome for discovering recurrent mutations (single nucleotide aberrations), indels (any number of nucleotides, possibly resulting in frame shift), translocations (rearrangements of regions of nonhomologous chromosomes), or inversions (chromosomal breaks where a piece of DNA is reversed and reinserted), as well as large-scale structural variations (Figure 1) . In sarcoma research, Paniz-Mondolfi et al. have used NGS,
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Figure 1. An overview of genomic platforms and a summary of the genomic findings in sarcoma research. Bulk tumor samples or single tumor cells isolated from the sarcoma/cancer patients can be analyzed at various genomic levels, including DNA, RNA and small RNA. At the DNA level, the analytical platforms include DNA microarrays, fluorescent in-situ hybridization (FISH), comparative genomic hybridization (CGH), DNA sequencing, single nucleotide polymorphism (SNP) arrays for identifying copy number aberrations (CNAs), SNPs and loss of heterozygosity (LOHs), DNA sequencing (e.g., whole genomic sequencing, WGS and whole exon sequencing, WES) for identifying point mutations, insertions and deletions (indels), translations, and inversions, and bisulfite conversion-based methods for methylation studies (e.g., methylation arrays and bisulfite sequencing) for identifying differentially methylated CpG sites and regions. At the RNA levels, the commonly used platforms include expression microarrays and RNA sequencing for identifying differentially expressed mRNAs, long noncoding RNAs (lncRNAs), and long intergenic noncoding RNAs (lincRNAs) in different types of samples and conditions. At the small RNA level, RNA sequencing, microarray and quantitative reverse transcription PCR are frequently used to discovering differentially expressed microRNAs (miRNAs) in sarcomas or cancers. Examples of the applications of these genomic platforms in sarcoma research are listed in color-coded boxes based on the genomic platforms (see text for details).
in conjunction with histological (cell level), ultrastructural (organelle level) and immunohistochemical (proteinlevel) analyses, to identify a common clonal origin of the epithelial and sarcomatous cell types in primary cutaneous carcinosarcoma [20] . Since the origin and biological aspects of this biphenotypic tumor are poorly understood, it is unclear if both epithelial and sarcomatous elements share a common clone of origin. The study has revealed that a point mutation in the exon 5 of TP53 presents in both epithelial and sarcomatoid components, indicating a common clonal origin [20] . The study has also shown that there was a shared antibody reactivity against the progenitor cell marker, epi thelial cell adhesion molecule (EpCAM), in both components. These findings are clinically relevant, because the TP53 point mutation could serve as a diagnostic marker, which sheds light on the histopathogenesis of this rare tumor. Moreover, the EpCAM overexpression may provide a potential target for anti-EpCAM antibodies in the treatment of this sarcoma. Additionally, recurrent nuclear receptor coactivator 2 (NCOA2) rearrangements and myogenic differentiation 1 (MYOD1) transactivating mutations have been identified in congenital spindle cell and adult spindle cell rhabdomyosarcoma (RMS), respectively [21, 22] . However, a relatively large number of osteosarcomas may have undergone chromothripsis, which is a massive genomic rearrangement phenomenon that may involve up to thousands of clustered chromosomes in a single catastrophic event during tumorigenesis [26, 27] .
DNA methylation analysis
One of the major regulators of RNA transcription is DNA methylation, which is an epigenetic process by which a methyl group is added to the cytosine of a cytosine-guanine (CpG) dinucleotide (Figure 1) . Dense CpG regions, known as CpG islands, are often associated with gene promoters, and are thus typically unmethylated. Promoter methylation can repress gene transcription by obstructing the binding sites of transcription factors. It can also initialize downstream processes, which make the surrounding chromatin (DNA-protein complexes that encompass the structural components of chromosomes) structure less accessible to transcriptional machinery. Aberrations in DNA methylation, particularly specific to loci of tumor suppressors or other key genes, has been shown to be involved with many malignancies [28] [29] [30] .
The study of aberrations in DNA methylation specific to sarcomas is still in its early stages. Aberrations in O6-methylguanine-DNA methyltransferase (MGMT), an important enzyme involved in DNA methylation, have been discovered in uterine sarcoma and carcinosarcoma [31] . However, the MGMT promoter methylation was found to be a rare event in soft tissue sarcoma by Jakob et al., noting only 6 out of 75 tumor samples examined showing MGMT gene silencing through methylation [32] . [37] . One of the earliest DNA-methylation studies in osteosarcoma utilized bisulfite sequencing to identify the loss of imprinting at IGF2 and H19 via methylation changes at transcription factor regulators [38] . A genomewide DNA methylation analysis was conducted in different histological types of RMS, which revealed a significantly higher PTEN hypermethylation and gene silencing in the embryonal subtype when compared to the alveolar 181 subtype [23] . Based on methylation characteristics, the study has also identified a subset of embryonal RMS with worse overall survival that is independent of stage, age and tumor site involvement. PTEN is one of the most frequently mutated tumor suppressors in human cancers and is also essential for embryonic development by modulating G1 cell cycle progression through the FGFR4/PI3K/AKT axis [39] . Hence, the finding that PTEN methylation/mutation occurs frequently in a specific subset of embryonal tumors may lead to the development of a predictive biomarker for those patients who may benefit from therapeutic inhibition of the FGFR4/PI3K/AKT axis. Finally, the oncogenic role of IDH2 in altering DNA methylation in sarcomas has been shown by Lu et al. [40] DNA-demethylating agents were used to reverse the effects of hypermethylation from mutant IDH2. Although only relatively few methylation studies have been incorporated into sarcoma research, these results show an immense untapped potential for methylation analyses in the future treatment and understanding of sarcomas.
Transcriptomic analysis
Since transcriptional regulation is a complex process, including methylation, transcription factor binding, and chromatin/histone modifications, it is preferable to directly measure the abundance of RNA transcripts in a tumor. RNA analysis can complement DNA or methylation analyses, which may discover new dysregulations that are not observable at either level. Many key cancer-associated molecules, such as oncogenes and tumor suppressor genes, have been discovered by analyzing the abundance of mRNA transcripts [41] [42] [43] . Thus, it is highly valuable to comprehensively examine the transcripts of all expressed genes in tumor cells (Figure 1) . Microarray-based expression profiling has been extensively used in sarcoma research [44] . For instance, Khanna et al. used a cDNA microarray approach to identify ezrin as a potential metastasis-associated molecule by comparing the gene expression profiles between two clonallyrelated higher and lower metastatic osteosarcoma cell lines [45] . Bulut et al. have reported that two small molecule inhibitors of ezrin, NSC305787 and NSC668394, inhibit metastatic progression of osteosarcoma cells in both in vitro and in vivo experimental models [46] . Celik et al. have expanded on these results by studying the pharmacokinetics of NSC305787 and NSC668394 in mice and identifying key ezrin-mediated biological pathways that can be used as pharmacodynamics markers. They conducted a microarray analysis to show that inhibiting ezrin in osteosarcoma upregulates stress-response genes, including PTGS2, ATF3, DDIT3, DDIT4, TRIB3, and ATF4 [47] . The group has concluded that DDIT4 might be used as a surrogate pharmacodynamic marker to indicate responsiveness towards ezrin inhibition. Expression profiling has also been used to predict patient prognosis or chemotherapy. Man et al. has identified a 45-gene signature that can discriminate between good and poor responders in osteosarcoma [48] .
TRIP6 was identified as an oncogene partially responsible for the increased cell migration and invasion in Ewing sarcoma cell lines that are independent of the EWS/FLI1 fusion [49] .
Besides microarrays, RNA-Seq has become a popular tool in sarcoma research. Town et al. have discovered that LINGO1 is expressed in over 90% of Ewing sarcoma cases, but not in other tissues outside of the brain. LINGO1 does not only have biomarker implications, but it can also be a cell-surface gateway to shuttle drugs for eliminating Ewing sarcoma cells specifically [50] . In contrast, Sankar et al. have
used RNA-seq to analyze the transcriptional profiles driven by EWS/ETS fusions in Ewing sarcoma. They have shown that the LSD1 inhibitor HCI2509 successfully reverses both up-and down-regulated transcriptional profiles and oncogenic phenotypes downstream of the fusions, which can restore cell morphology and induce apoptosis [51] .
Another study has detected a novel fusion between BCOR and CCNB3 on the X-chromosome by a RNA-Seq analysis of samples from individuals with small round cell tumors of the bone, a new type of Ewing sarcoma lacking the canonical EWSR1-ETS translocation [52] . Lastly, Micci et al.
have demonstrated that endometrial stromal sarcoma (ESS) is much more heterogeneous than previously thought, [53] Specifically, they found that six out of eight high-grade ESS tumors do not display previously described transcriptional aberrations, including the YWHAE-NUTM chimeric transcript. The study described new variants of ZC3H7-BCOR and its reciprocal BCOR-ZC3H7, as well CREBBP and MLLT4 involvement in two new fusions from lowgrade ESS tumors, finding subgroups of high-risk patients that may have been missed by current clinical models. Recently, long noncoding RNA (lncRNA) and long intergenic noncoding RNA (lincRNA) with >200 nucleotides in length have captured significant interests. They are expressed in tissue-specific manner with very low sequence conservation. Initially, they were considered as transcriptional noise, but many of the lncRNAs and lincRNAs have been shown to carry specific functions and play a role in cancer, such as sarcoma [54] [55] [56] [57] . An important property of these noncoding RNAs is that they can be used as cancer biomarkers. For instance, a lncRNA signature can predict clinical outcomes and prognoses in soft tissue sarcoma [58] . The lncRNA HOTAIR is a prognostic biomarker in chondrosarcoma [59] . lncRNAs are commonly identified via microarrays, RNA-Seq or quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis [60] [61] [62] [63] . A recent study described two novel and possibly tumor suppressor lncRNAs, LOC285194 and BC040587, whose expressions are either lost or mutated in osteosarcoma [63] . The lncRNA BCAR4 and lnc277
(Ewing sarcoma-associated transcript 1, or EWSAT1) have been also shown to play a tumorigenic role in osteosarcoma and Ewing sarcoma, respectively, via completely opposite mechanisms of gene activation and repression [60, 62] . Other lncRNAs have been implicated in chemoresistance, metastasis and tumor cell growth [59] [60] [61] . This is a rapidly growing field in sarcoma research with many lncRNAs yet to be identified and functionally characterized, so that they can be potentially used as biomarkers and therapeutically targets in sarcomas.
miRNA analysis
miRNA are a class of small non-coding RNAs, from 18 to 24 nucleotides in length, that are capable of modulating gene expression at the post-transcriptional level by binding to the 3' untranslated regions of target mRNAs, resulting in their degradation and/or inhibition of translation [64] .
Hence, miRNAs function as important regulators in diverse biological processes including those that contribute carcinogenesis [65] . Dysregulation of miRNA expression occurs in many cancers, rendering them to act as oncogenes or tumor suppressors [66, 67] . miRNAs and their target genes can, therefore, be exploited as novel therapeutic targets and biomarkers (Figure 1) . miRNA has been studied to identify differential expressions between tumors and healthy controls and in different tissue types, as well as to discover biomarkers for chemoresistance and prognosis [68] [69] [70] [71] [72] . In sarcoma research, miR-143/miR-145 cluster expression has been implicated in cancer stem cell-associated self-renewal and tumorigenicity [73] . EWS-FLI1 aberrant transcription factor inhibits miR-30a-5p expression, resulting in increased tumor cell proliferation and invasion in Ewing sarcoma [74] . Ugras et al. have discovered that miR-143 is a tumor suppressor by inhibiting proliferation and inducing apoptosis in liposarcoma [75] . In addition, a microarray approach has been used to identify upregulation of miR-135b-5p and miR146a-5p in four highly invasive osteosarcoma cell lines in comparison to noninvasive cell lines [76] . In contrast, the expression of miR-133a and miR133b in osteosarcoma is lower than healthy human skeletal muscle samples. Overexpression of miR-133b reduces tumor cell proliferation, migration, invasion and induces apoptosis in osteosarcoma cell lines, indicating a tumor suppressor role of miR-133b in osteosarcoma [77] . Recently, mature miRNAs labeled with unique DNA tags have been profiled in human sarcomas and normal tissues. Low expression of miR-145 in pleomorphic RMS, liposarcoma and synovial sarcoma was observed. Muscle-specific miR-133, miR-1 and miR-206 are expressed lower in liposarcoma and synovial sarcoma, indicating they may act as tumor suppressors in these tumors [78] . In addition, recent studies have employed qRT-PCR for osteosarcoma research. For instance, down-regulation of miR-335 is significantly associated with lymph node metastasis, indicating that this miRNA inhibits cell migratory and invasive properties [79] .
miR-183 is involved in the development and progression of osteosarcoma with promising prognostic implications [80] .
Finally, loss of TP53-dependent miR-34c expression increases the expression of RUNX2 transcription factor, which increases cell proliferation [81] .
Single-cell genomics
Tumor heterogeneity occurs both between tumors (inter-tumor heterogeneity) and within tumors (intratumor heterogeneity). Tumor heterogeneity gives rise to significant challenges in identifying robust molecular prognostic markers and predicting which patients will benefit from specific therapies. Recently, single cell genomic approaches have made tremendous advances in characterizing tumor cell heterogeneity and its role in disease progression, diagnosis and treatment. Furthermore, they can assist in early detection of rare tumor cells and monitoring circulating tumor cells. Single-cell DNA and RNA sequencing are two important and widely used tools for single-cell analysis [82, 83] . From distinguishing colorectal
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tumor cell heterogeneity with distinct survival probabilities, elucidating generation of point mutations leading to clonal diversity in breast cancer and analyzing the intra-tumoral metastatic melanoma cells with higher chemoresistance, these techniques have transformed the cancer genomics field [84] [85] [86] . However, the application of single cell genomics in sarcoma research is still in its infancy. Since the rarity and heterogeneity of pediatric sarcoma samples pose a major challenge for biomarker and drug development, single-cell analysis would be an invaluable methodology in sarcoma research.
Data integration
With the rapid development of technologies to elucidate genomic aberrations in sarcomas as described above, the opportunity for studying cancer genomics holistically is becoming a reality. Due to the complex nature of sarcomas and the relatively small sample sizes in sarcoma studies, unleashing the power of statistics and data integration is critical for the identification of prognostic biomarkers and therapeutic targets in cancer patients (Figure 2) . Hence, novel algorithms have been developed for data integration [87] [88] [89] [90] [91] [92] [93] [94] [95] . Data integration can refer to many different research areas, such as integrating different omics data sources, integrating molecular data with phenotypic and clinical data (e.g. tumor subtype, pathology, survival status, or presence of metastatic lesions), and integrating molecular data with already known biological data from online sources (e.g. pathway or gene-enrichment analysis). A common issue in genomic data integration arises from ignoring if the datasets generated have the same distribution or not. To analyze, compare, and integrate data from disparate genomic platforms, it may be essential to ensure the distributions of the data are from the same family by transforming the data to fit the statistical analysis. For instance, Borgwardt et al. have developed a kernelbased method to evaluate whether two biological datasets are from the same distribution [96] . This statistical method used the maximum discrepancy between function means as the basis of a test statistic, which allows the use of a wide array of data types that arise in molecular biology, such as sequences, graphs, and other common structured data types. The main goal of data integration is to provide added power to traditional single-platform analyses by uncovering shared information between multiple data sources or utilizing already known biological information. Shared or overlapping results may implicate biologically meaningful processes or mechanisms, such as changes in transcript levels due to alterations in DNA copy number or methylation. Further, phenotypic or clinical data can help to determine if these changes are present due to a biologically meaningful process that may be linked to the clinical treatment of the disease. In this review, three categories of genomic data integration are discussed, i.e. subtype discovery, pathway identification and feature selection of aberrantly regulated genes.
Due to inter-tumor heterogeneity, subtype discovery is a central component of many molecular studies in cancer research. The goal is to stratify morphologically or histologically similar tumors into subtypes based on molecular expression patterns and clinical covariates by unsupervised statistical learning, i.e. without invoking prior biological knowledge. These analyses have indeed been successful for many cancers, including breast malignancies [97] . Due to the desire of incorporating many data sources to create a better understanding of cancer subtyping, integrative unsupervised clustering methods have been developed. For example, a study from TCGA on endometrial carcinoma introduced a novel clustering-based integration strategy called SuperCluster to characterize new groupings of patients based on several genomic platforms such as somatic CNAs, mutation and substitution frequency, as well as clinical variables such as histology and tumor grade [98] . In this seminal work, the authors could classify patients with endometrial carcinoma into four subtypes, which was based on several data sources. Another algorithm for unsupervised integrative classification is iCluster [91] . This algorithm makes use of a latent-variable modeling approach to stratify cancer patients based on information shared between the data sources, and has been used to successfully build robust patient strata in multiple cancer studies [88, 90, 91, 98] .
Genomic pathways are of vital importance to cancer research because they can link what appears to be distinct gene information into a common biological context. Furthermore, discovering pathway aberrations can lead to effective selection of candidate therapeutics for a cancer type or subtype. The utility of this integration between molecular and known biological data can be further enhanced through incorporation of multiple genomic platforms in the analysis. One commonly used integrative strategy is to interrogate each data source separately to A workflow for data gathering, bioinformatic analysis and data integration for cancer genomics research. The genomic data are generated and/or assembled in different analytical platforms together with various sources of information, such as biological databases and clinical information. These data and information are subjected to bioinformatic analysis and data integration using different algorithms and methods (see text for details). Examples of the analytical outputs include identification of disease subtypes, differentially expressed genes or regions, and aberrant biological pathways and gene networks. These output results can be used to discover therapeutic targets and prognostic or predictive biomarkers, and generate new hypotheses for future studies. The development of new experimental approaches and acquiring new type of molecular information will then allow the generation of new types of genomic data or increase the resolution of the genomic data for a new cycle of bioinformatic analyses, data integration, and applications. 185 find significant aberrations, and then input the top results from each platform into a pathway enrichment tool, such as MetaCore or Ingenuity Pathway Analysis (IPA) [99] . Other groups have developed algorithmic integration strategies that account for pathway membership, such as FSMKL and PARADIGM. [100] FSMKL is an algorithm that utilizes a kernel-based machine learning strategy (multiple kernel learning or MKL) to summarize pathway information across platforms, develop a model of some clinical characteristic (i.e. survival), and determine which pathways were most instrumental in the process [89] . In contrast, PARADIGM is an algorithm that encodes different sources of information into a factor graph, i.e. a graphical model that allows for an efficient computation of marginal distributions through the product-sum algorithm, and clusters based on aberrations in those factors with respect to each pathway of interest [100] .
This approach is used specifically to infer aberrant pathway activities, and is instrumental in detecting patientspecific pathway activity. PARADIGM has been used rather extensively to date for integrative pathway analysis, including in TCGA-related studies [98, 101, 102] . For example, in analyzing breast cancer, PARADIGM was used to elucidate ESR1 and FOXA1 as cohort-wide hubs in addition to MYC, FOXM1 and MYB as hubs in aromatase-inhibitor-resistant tumors with gene expression and copy number data [101] .
Furthermore, concordant PI3K, TP53, and RB pathway aberrations between breast cancer subtypes were inferred based on loss of heterozygosity (LOH), copy number, mutation, expression, and proteomic data, painting a comprehensive picture of the molecular landscapes present in breast tumors [102] .
Next are algorithms used to discover or select aberrant biomarkers and their use for supervised statistical learning, i.e. to build classification, regression, or survival models. Since there has not been a wealth of validated biomarkers in sarcoma research, integrating data for more robust biomarker models with clinical data could be immensely valuable to researchers. Some of these algorithms select biomarkers based on biological relationships between data sources, e.g. miRNA regulation of mRNAs as well as the corresponding proteomic information [87, 95] . Others incorporate intrinsic feature selection methods to build models, such as iBAG, a model-based Bayesian approach that uses Lasso regression to impart sparsity to remove non-significant variables and infer potential interactions between cross-platform features in order to build models with clinical relevance [93] . A similar method was designed by Huopaniemi et al., but uses latent variable models to summarize similar features to build classifiers, which has the added benefit of measuring the shared and platformspecific effects to determine what level of information is most important for the particular integrative model [94] . They found that the method can detect the contribution of single platforms and their joint contribution to the overall effect on clinical variables. This indicates that joint molecular platform information may be crucial for the development of effective models to understand cancer pathogenesis. As an example of data integration in sarcoma research, Renner et al. have utilized a clustering-based gene selection approach for integrating DNA methylation and gene expression data in high-grade soft tissue sarcomas [37] . They could stratify the patients into seven groups and discovered 30 novel biomarkers.
Current challenges and future directions
One of the ultimate goals of elucidating aberrant genes and gene products is to develop targeted therapeutic approaches [103] . Nonetheless, despite the advances in genomic research and integration as noted above, there are still significant challenges before translating these findings into the clinic. A few broad difficulties that are being encountered include a lack of consensus among researchers and lack of standardization of the most relevant genomic features, an increased burden on clinicians and patients, infrastructural difficulties in storing and interpreting the data, and electronic health record (EHR)-related issues in patient privacy and accessibility of data [104] [105] [106] . Fortunately, both academic and commercial efforts are underway to translate genomic findings into clinically-actionable results as well as design and build the infrastructure necessary to tackle EHR issues [107] [108] [109] [110] [111] [112] . The use of genomic findings is mostly in the early phase when it comes to clinical applicability in sarcoma, i.e. the actionable discoveries have not been used to guide clinical decisions [113] . However, a recent study by Uzilov et al. has shown that using integrative genomic approaches in the clinical setting for colorectal, breast, and medullary thyroid carcinomas has led to significantly enhanced personalized therapeutic strategies for clinicians [114] . Thus, we believe that integrating genomic findings into clinics and hospitals will provide more effective patient stratification and guide therapeutic options Although targeted therapy is a hallmark in the treatment of blood cancers, such as leukemia, there has been a wealth of successful pharmacogenomic discoveries in solid tumors as well [115] [116] [117] . These include Tamoxifen in treating ER+ breast cancer and EGFR-directed therapies for lung cancer patients [117] . In addition, the patient's genotype information may be used to modify therapy, such as in the case of Irinotecan in metastatic colorectal patients. Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is involved in metabolizing Irinotecan's more potent metabolite SN-38 to inactive SN-38-glucuronide. For patients with the reduced activity UGT1A alleles, treatment with Irinotecan may result in increased toxicity [117] . Hence, prospective genotyping of the UGT1A locus would facilitate optimizing the chemotherapy for individual patients.
Targeted therapeutic strategies are also being explored in the treatment of sarcomas, but unfortunately, most of them have not significantly improved the outcomes of patients with metastatic disease, where innovative therapeutic strategies are most needed [118] . In this regard, the NCI's TARGET initiative has embarked on comprehensive genomic characterizations of several pediatric cancers, such as osteosarcoma, to identify therapeutically applicable targets. The Stand Up To Cancer (SUTC) program and the St. Baldrick's Foundation have funded the Pediatric Dream Team, who will harness genomic information to identify novel immunotherapy targets for pediatric cancers, including sarcomas. These genomic efforts will provide valuable information for the sarcoma research community to identify clinically useful targets and biomarkers for future clinical trials. Furthermore, targeted therapy will have added benefits by integrating many other sources of data besides genomic data, such as phenotypic, health record, social media, transactional, and others in a holistic view of systems medicine being described as "P4 Medicine" by the Institute for Systems Biology (ISB) [119, 120] . With these multi-institutional efforts, we believe that data integration represents a promising strategy for the discovery of targeted treatment in sarcoma patients in the near future.
Although the information presented in this review covers a broad spectrum of genomic characterizations in tumors, the above techniques can only help to elucidate regulation on the genetic, transcriptional, and post-transcriptional level, which may not represent a functional view of the gene products. A wealth of proteomic and metabolomic technologies has been developed to gain insight into some of these downstream mechanisms. Post-translational regu latory mechanisms of interest, including proteinprotein interactions, glycosylation, phosphorylation, and ubiquitination, are being studied extensively to shed light on aberrations associated with diseased states [121] [122] [123] [124] .
Additionally, being primarily focused on the genomics of a tumor itself, this review did not begin to touch upon the other complexities involved in cancer, primarily related to tumor heterogeneity and complex microenvironment interactions. Many researchers are also exploiting the evolutionary nature of cancer from a complex ecosystems perspective, which may shed some light as to how different molecular mechanisms allow cells to fill different necessary niches for cancer adaptation and progression [125] [126] [127] [128] [129] .
Specifically, one group leveraged an integrative genomic strategy using whole transcriptome sequencing, copy number analysis, fluorescent in-situ hybridization, qRT-PCR and immunohistochemistry, to determine the molecular basis for the evolution of dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma. They have found that the event was characterized by an epithelial-mesenchymal transition-like process and loss of chromosome 22q [130] . This type of integrative approach is crucial to cancer treatment, as the diversity in cell populations can allow tumors to be robust to environmental perturbations, such as treatment [131] .
Beyond the tumor itself, it is also very difficult to dif fe rentiate the genomic features from different components of its microenvironment. It is becoming clear that the microenvironment, host factors, and immune response play a crucial and complex role in tumorigenesis, chemoresistance and metastasis [132, 133] . In order to develop the next generation of effective therapeutics, genomic and molecular analyses beyond cancer cells are urgently needed. For example, researchers are studying the roles of both tumor-derived microvesicles and cytokines with respect to chronic inflammation in the tumor microenvironment [134, 135] .
Briefly, tumor-derived microvesicles can transport anything from proteins to RNA (long or short, coding or noncoding) to even DNA from tumors to other cells of the microenvironment for complex signaling mechanisms not yet well understood, but likely integral to tumor progression. They can, therefore, be instrumental as biomarkers and even therapeutic targets [134] . In contrast, cytokines are released under acute inflammation to target 187 pathogens, but may alternatively be exploited by tumors for both initiation and progression of cancer. Their roles in mediating the generation of reactive oxygen and nitrogen species as well as mechanisms for epithelial mesenchymal transition, angiogenesis and metastasis implicate their potential as biomarkers and therapeutic targets in cancer as well [135] . Understanding signaling and mechanical mechanisms between components in this complex adaptive system, including the extracellular matrix, vasculature, and other heterogeneous cell types, will be a crucial next step to fully understand cancer [136] .
It is also important to understand the limitations of the genomic techniques. Since genomics platforms only provide a "snapshot" in time of a continuous and adaptive complex system, determining true system perturbations from analysis of different tumors with different genomic backgrounds is very difficult. The dynamic context of the system also needs to be analyzed. While systems biology efforts are underway to understand biological complexity on smaller scales, the models are a long way from being able to handle large-scale genomic data. Additionally, the ideal scenario would be to have rich longitudinal data for different genomic platforms for each sample, where more efforts are urgently needed. Regardless, genomic platforms and data integration methods are merely tools for hypothesis testing and validation, and it should be noted that no model can fully describe a complex cancer system, but many simplified models are still highly useful for biomarker and therapeutic development. Therefore, we believe that the clinical treatment of sarcomas will benefit greatly from advances in genomic research and data integration.
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